文献速递前列腺癌

转移性前列腺癌患者胚系致病变异患病率研究

Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer.
PubMed 文献 · BJU Int · 2025-09-02

这项前瞻性多中心队列研究在15个中心对779例转移性前列腺癌患者进行BRCA1、BRCA2、ATM、CHEK2和PALB2胚系基因检测,发现46例(5.9%)携带DNA损伤修复基因胚系致病变异,其中CHEK2、ATM和BRCA2变异显著高于参考人群,且第二原发癌、年轻乳腺癌家族史、胰腺癌家族史或犹太血统者携带可能性最高。

要点

  • 779例转移性前列腺癌患者中5.9%携带DNA损伤修复基因胚系致病变异。
  • CHEK2、ATM和BRCA2变异显著高于参考人群,BRCA1和PALB2无显著升高。
  • 第二原发癌、年轻乳腺癌或胰腺癌家族史、犹太血统者应优先考虑基因检测。

核心结论

  • CHEK2、ATM和BRCA2胚系致病变异与男性转移性前列腺癌相关。
  • 多种因素增加携带胚系致病变异的可能性,应据此提供基因检测。

研究设计与样本

  • 前瞻性多中心队列研究,纳入15个中心779例转移性前列腺癌患者。
  • 提供BRCA1、BRCA2、ATM、CHEK2和PALB2胚系基因检测。

主要发现

  • 779例中46例(5.9%)携带DNA损伤修复基因胚系致病变异。
  • 多数变异位于CHEK2(1100delC变异)、ATM和BRCA2。
  • CHEK2、ATM和BRCA2变异患病率显著高于参考人群,比值比分别为2.4、2.8和3.1。
  • BRCA1和PALB2变异患病率无显著升高。

关键数值与推荐

  • 携带胚系致病变异可能性最高的因素:第二原发癌、一级或二级亲属50岁前患乳腺癌、胰腺癌家族史或犹太血统。

临床怎么用

  • 对转移性前列腺癌患者,尤其携带上述高风险因素者,应提供胚系基因检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the prevalence of germline pathogenic variants (gPVs) in genes associated with female breast cancer in Dutch patients with metastatic prostate cancer (mPCa). PATIENTS AND METHODS: In this prospective multicentre cohort study (n = 15 centres), germline genetic testing of the genes BRCA1, BRCA2, ATM, CHEK2 and PALB2 was offered to patients with mPCa. We assessed the prevalence of gPVs and compared it to a reference population of 16 823 individuals who underwent genetic testing for non-oncological conditions. Additionally, we identified factors that increased the likelihood of carrying a gPV. RESULTS: A total of 779 patients with mPCa underwent germline genetic testing, of whom 46 (5.9%) had a gPV in a DNA damage repair gene. Most gPVs were found in CHEK2 (1100delC variant), ATM and BRCA2, all significantly more prevalent than in the reference population (odds ratios 2.4, 2.8 and 3.1, respectively). The prevalence of gPVs in BRCA1 and PALB2 was not significantly increased. Patients with a second primary cancer, a first- or second-degree relative with breast cancer at age < 50 years, or pancreatic cancer, or Jewish ancestry had the highest likelihood of carrying a gPV. CONCLUSION: We found that gPVs in CHEK2, ATM and BRCA2 were associated with men presenting with mPCa. Several factors increased the likelihood of carrying such a variant and, in these cases, healthcare professionals should be aware of the need to offer germline genetic testing.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Vlaming M, Koole W, van Moorselaar RJA, et al. Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer. BJU Int. 2025. PMID: 40891997. doi:10.1111/bju.16916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。